Exclusive license agreement reached for subcutaneous formulation

  • Xeris Biopharma and Amgen have reached a license agreement for a Thyroid Eye Disease treatment
  • Amgen will develop, manufacture, and commercialize the formulation of teprotumumab using Xeris’ XeriJect technology
  • Xeris may receive up to $75 million based on development and regulatory milestones, as well as sales milestones
  • Xeris will also receive royalties on future sales of Tepezza using XeriJect technology

Xeris Biopharma has entered into an exclusive worldwide license agreement with Amgen for a subcutaneous formulation of a Thyroid Eye Disease treatment. Under the agreement, Amgen will be responsible for the development, manufacturing, and commercialization of the formulation of teprotumumab using Xeris’ XeriJect technology. Xeris stands to receive up to $75 million in milestone payments based on development, regulatory, and sales milestones. Additionally, Xeris will receive royalties on future sales of Tepezza, the brand name for teprotumumab in the U.S., utilizing XeriJect technology.

Public Companies: Xeris Biopharma (Unknown), Amgen (Unknown)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides clear and concise information about Xeris Biopharma entering into a license agreement with Amgen for a subcutaneous formulation of a Thyroid Eye Disease treatment. It mentions the involvement of both companies, the use of Xeris’ XeriJect technology, and the potential financial benefits for Xeris. The information provided is specific and does not contain any irrelevant or misleading details. However, more context about the significance of this agreement and the potential impact on patients or the market could have been included.

Noise Level: 8
Justification: The article provides a brief overview of a licensing agreement between Xeris Biopharma and Amgen for a subcutaneous formulation of a Thyroid Eye Disease treatment. However, it lacks in-depth analysis, scientific rigor, and evidence to support the claims made. The article does not explore the long-term trends or antifragility of the systems involved. It also does not hold powerful people accountable or provide actionable insights or solutions. Overall, the article contains mostly filler content and lacks substance.

Financial Relevance: Yes
Financial Markets Impacted: Xeris Biopharma, Amgen

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: This news article pertains to a financial agreement between Xeris Biopharma and Amgen regarding a subcutaneous formulation of a Thyroid Eye Disease treatment. There is no mention of an extreme event or its impact.

Reported publicly: www.marketwatch.com